AMGEN INC

Amgen Inc (ticker AMGN) is a biotechnology leader producing human therapeutics rooted in genetically engineered proteins, monoclonal antibodies, and next-generation biosimilars, primarily serving specialty physicians, hospitals, and integrated healthcare systems grappling with cancer, renal disease, and autoimmune disorders. Operating under the Biological Products (No Diagnostic Substances) classification with SIC 2834, the company blends discovery research and large-scale manufacturing to deliver flagship oncology, nephrology, and inflammation franchises plus supportive care agents to health plans and governments worldwide. Its balance between growth and risk depends on navigating FDA and equivalent global regulatory approvals, patent cliffs, reimbursement pressure, and supply-chain vigilance around critical cell culture inputs. Investors monitor the pace of new indications, biosimilar competition, and updates to legislative pricing reforms, all reflected in the most recent Form 10-Q filed November 1999, given the public disclosure cadence. CIK 318154 anchors the filing record, so view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025